By contrast, Li et al. demonstrated that MET decreases PD-L1 expression in hepatocellular carcinoma by the GSK3β-mediated post-translational modification/degradation of PD-L1 protein, rather than by its transcriptional regulation [26]. The gene discussed is GSK3B; the disease is hepatocellular carcinoma.